Breaking News


Bexarotene therapy for mycosis fungoides and Sézary syndrome


A retrospective study of 40 patients with mycosis fungoides and 26 patients with Sézary syndrome evaluated their response to the retinoid bexarotene (150-300 mg/m2 daily). The majority of patients (79%) completed over 1 month of therapy with a median 6 months.Complete, partial and stable responses were seen in 9, 35 and 23% of patients, respectively. The median time to maximal response was 3 months, with a median response duration of 8 months. All patients had grade II central hypothyroidism and hyperlipidemia. Bexarotene was well tolerated in most patients in this study and responses were seen in almost 50% of patients (Abbott, R.A. et al. Br J Dermatol 2009, 160(6): 1299).

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list